A phase II randomized, active-controlled study to assess the safety, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin over 12 weeks in treatment-naive patients with chronic hepatitis C.

Trial Profile

A phase II randomized, active-controlled study to assess the safety, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin over 12 weeks in treatment-naive patients with chronic hepatitis C.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Celgosivir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Carrus Capital Corporation
  • Most Recent Events

    • 03 Dec 2007 Results at 4-weeks have been presented for 10 evaluable patients.
    • 30 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top